Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

著者: Roger Stupp, Monika E. Hegi, Thierry Gorlia, Sara Erridge, James Perry, Yong-Kil Hong, Kenneth Aldape, Benoît Lhermitte, Torsten Pietsch, Danica Grujičić, Joachim P. Steinbach, Wolfgang Wick, R. Tarnawski, Do‐Hyun Nam, Peter Hau, Astrid Weyerbrock, Martin J B Taphoorn, Chiung‐Chyi Shen, Nalini Rao, László Thurzó, Ulrich Herrlinger, Tejpal Gupta, Rolf‐Dieter Kortmann, Krystyna Adamska, Catherine McBain, Alba A. Brandes, J. C. Tonn, Oliver Schnell, Thomas Wiegel, Chae‐Yong Kim, Burt Nabors, David A. Reardon, Martin J. van den Bent, Christine Hicking, Andriy Markivskyy, Martin Picard, Michael Weller - The Lancet 2014 被引用: 1,019